About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Texas | 12,973 Studies Near You | Clareo Health

Clinical Trials LocationsTexas

Clinical Trials in Texas

Discover 12,973 clinical trials near Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 12321-12340 of 12,973 trials

COMPLETEDPhase 155 miles

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

NCT00383370

To assess the safety and tolerability of repeated intravitreal (ITV) administration of VEGF Trap.

Neovascular Age Related Macular Degeneration

Regeneron Pharmaceuticals20 participantsStarted Oct 2006

Fort Myers, Florida, United States • Wichita, Kansas, United States • Hagerstown, Maryland, United States +3 more locations

COMPLETEDPhase 355 miles

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955

This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.

Takeda669 participantsStarted Jun 2007

Ozark, Alabama, United States • Tallassee, Alabama, United States • Long Beach, California, United States +38 more locations

Find Trials by Condition in Texas

Breast Cancerin Texas Lung Cancerin Texas Prostate Cancerin Texas Colorectal Cancerin Texas Melanomain Texas Leukemiain Texas Lymphomain Texas Pancreatic Cancerin Texas Ovarian Cancerin Texas Brain Cancerin Texas Diabetesin Texas

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3116 miles

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

NCT00627016

The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.

Gastroesophageal Reflux

Takeda305 participantsStarted Mar 2008

Tucson, Arizona, United States • Anaheim, California, United States • Garden Grove, California, United States +40 more locations

COMPLETED116 miles

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

NCT00135447

The purpose of this study is to find out the frequency of the I50L substitution among patients experiencing treatment failure on an atazanavir-containing regimen.

Bristol-Myers Squibb5,000 participantsStarted Sep 2004

Phoenix, Arizona, United States • Beverly Hills, California, United States • Beverly Hills, California, United States +81 more locations

COMPLETEDPhase 3126 miles

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359

The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).

Cystic Fibrosis

Gilead Sciences166 participantsStarted May 2005

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Phoenix, Arizona, United States +50 more locations

COMPLETEDPhase 3126 miles

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820

This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.

Novartis Pharmaceuticals526 participantsStarted Dec 2006

Novato, California, United States • Northglenn, Colorado, United States • Melbourne, Florida, United States +20 more locations

COMPLETEDPhase 3126 miles

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.

Takeda1,291 participantsStarted Apr 2008

Alabaster, Alabama, United States • Ozark, Alabama, United States • Green Valley, Arizona, United States +128 more locations

COMPLETEDPhase 4126 miles

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

NCT00095290

Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.

Bristol-Myers Squibb400 participantsStarted Sep 2004

Tustin, California, United States • Miami, Florida, United States • West Palm Beach, Florida, United States +89 more locations

COMPLETEDPhase 2127 miles

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

NCT00004584

The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.

Bristol-Myers SquibbStarted Dec 1999

Birmingham, Alabama, United States • Los Angeles, California, United States • Oakland, California, United States +35 more locations

COMPLETEDPhase 3127 miles

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224

Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset. The purpose of this study is to compare the effectiveness of ddI EC versus the standard form of ddI. Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).

Bristol-Myers Squibb120 participantsStarted Mar 1999

Birmingham, Alabama, United States • Los Angeles, California, United States • Oakland, California, United States +21 more locations

COMPLETEDNA127 miles

DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116415

The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.

HIV InfectionsAIDS

Bristol-Myers Squibb65 participantsStarted Mar 2002

Washington D.C., District of Columbia, United States • Orlando, Florida, United States • Columbus, Georgia, United States +6 more locations

COMPLETEDPhase 3127 miles

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

NCT00085644

The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are intolerant to, treatment with at least 1 nonsteroidal anti-inflammatory drug (NSAID) and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug (DMARD).

Ankylosing Spondylitis

Abbott315 participantsStarted Jan 2004

Birmingham, Alabama, United States • Mobile, Alabama, United States • San Francisco, California, United States +19 more locations

COMPLETEDPhase 3127 miles

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

NCT00035633

The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.

Chronic Hepatitis B

Bristol-Myers SquibbStarted Dec 2001

Birmingham, Alabama, United States • Tucson, Arizona, United States • La Jolla, California, United States +32 more locations

COMPLETEDPhase 3127 miles

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

NCT00035789

The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.

Chronic Hepatitis B

Bristol-Myers SquibbStarted Nov 2001

Birmingham, Alabama, United States • Tucson, Arizona, United States • La Jolla, California, United States +28 more locations

COMPLETEDPhase 3159 miles

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

NCT00002371

To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.

Bristol-Myers Squibb80 participantsStarted Jun 1996

Torrance, California, United States • Tampa, Florida, United States • Stony Brook, New York, United States +5 more locations

COMPLETEDNA159 miles

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002411

The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF. This study also examines how long these drug combinations are effective in lowering viral load (level of HIV in the blood).

Bristol-Myers SquibbStarted Mar 1998

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Fresno, California, United States +29 more locations

COMPLETEDPhase 3159 miles

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969

Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.

Smoking Cessation

Pfizer128 participantsStarted May 2008

Aurora, Colorado, United States • Farmington, Connecticut, United States • New Haven, Connecticut, United States +11 more locations

COMPLETEDPhase 4305 miles

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

NCT00121836

This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer. Patients received Xeloda 1000 mg/m² orally (PO) twice daily (BID) on Days 1-15, and Avastin 15 mg intravenously (IV) on Day 1 of each 3-week cycle. The anticipated time on study treatment was until disease progression or unacceptable toxicity. The target sample size was \<100 individuals.

Hoffmann-La Roche109 participantsStarted Jun 2005

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +54 more locations

TERMINATEDPhase 2565 miles

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

NCT00483977

The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.

Pfizer113 participantsStarted Jun 2007

Mobile, Alabama, United States • Tucson, Arizona, United States • Carmichael, California, United States +18 more locations

COMPLETEDPhase 2646 miles

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

NCT00232154

To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.

Pfizer72 participantsStarted Nov 2005

Alabaster, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +15 more locations

PreviousPage 617 of 649Next

Heart Diseasein Texas